Major cancer centers reveal survival data for advanced liver cancer treatment
NCT ID NCT07298538
Summary
This study looked back at medical records of 800 patients with advanced liver cancer that couldn't be surgically removed. Researchers examined how well patients did when treated with lenvatinib-based drug combinations, tracking survival rates up to 5 years. The goal was to understand real-world effectiveness and safety of these treatments across six hospitals.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, 300060, China
Conditions
Explore the condition pages connected to this study.